[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fM9L69jDGwanOCTaOTxnekJKEm6C2Ebo4f65aGbE3OgA":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":56,"rows":63},"UConn Health",[4],185,false,27,9,42346,7,143,[14,17,20,22,25,28,31,33],{"name":15,"count":16},"Substance Abuse",11,{"name":18,"count":19},"Alcoholism",10,{"name":21,"count":9},"Alcohol Abuse",{"name":23,"count":24},"Contingency Management",8,{"name":26,"count":27},"Alcohol Dependence",6,{"name":29,"count":30},"Depression",5,{"name":32,"count":30},"Gambling",{"name":34,"count":30},"Cigarette Smoking",[36,41,46,51],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT06954662","A Targeted Amino Acid Supplement for People With Parkinson's Disease","2025-09","Amino acid supplement",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT06846853","Gadopiclenol vs. Gadobutrol for Dynamic Contrast-Enhanced Pituitary MRI (Magnetic Resonance Imaging)","2026-06-30","Gadopiclenol",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT06027554","The Mito-Frail Trial: Effects of MitoQ on Vasodilation, Mobility and Cognitive Performance in Frail Older Adults","2027-03-01","Mitoquinone Mesylate",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT06731764","Novel Approaches to the Treatment of Hypothyroidism","2027-12-31","Levothyroxine",[57,58,59,60,61,62],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[64,89,107,131,149,167,191,213,258,295,332,368,397,415,433,451,469,494,518,536,561,586,611,636,663,681,699,724,751,776,794,819,837,864,889,911,935,958,988,1006,1024,1050,1077,1095,1118,1143,1167,1193,1211,1257,1281,1307],{"intervention":45,"totalTrials":65,"cells":66},1,{"EARLY_PHASE1":67,"PHASE1":70,"PHASE2":72,"PHASE3":74,"PHASE4":76,"NA":87},{"trials":68,"activeCount":69},[],0,{"trials":71,"activeCount":69},[],{"trials":73,"activeCount":69},[],{"trials":75,"activeCount":69},[],{"trials":77,"activeCount":65,"soonestReadout":44},[78],{"nctId":42,"briefTitle":43,"status":79,"phases":80,"primaryCompletion":44,"completion":44,"start":81,"enrollment":19,"conditions":82,"interventions":85},"RECRUITING",[61],"2025-03-25",[83,84],"Contrast Enhanced Images vs. Non-contrast Images","Gadopiclinol Enhanced Images vs. Gadobutrol Enhanced Images",[45,86],"Gadobutrol",{"trials":88,"activeCount":69},[],{"intervention":86,"totalTrials":65,"cells":90},{"EARLY_PHASE1":91,"PHASE1":93,"PHASE2":95,"PHASE3":97,"PHASE4":99,"NA":105},{"trials":92,"activeCount":69},[],{"trials":94,"activeCount":69},[],{"trials":96,"activeCount":69},[],{"trials":98,"activeCount":69},[],{"trials":100,"activeCount":65,"soonestReadout":44},[101],{"nctId":42,"briefTitle":43,"status":79,"phases":102,"primaryCompletion":44,"completion":44,"start":81,"enrollment":19,"conditions":103,"interventions":104},[61],[83,84],[45,86],{"trials":106,"activeCount":69},[],{"intervention":55,"totalTrials":65,"cells":108},{"EARLY_PHASE1":109,"PHASE1":111,"PHASE2":113,"PHASE3":115,"PHASE4":127,"NA":129},{"trials":110,"activeCount":69},[],{"trials":112,"activeCount":69},[],{"trials":114,"activeCount":69},[],{"trials":116,"activeCount":65,"soonestReadout":54},[117],{"nctId":52,"briefTitle":53,"status":79,"phases":118,"primaryCompletion":54,"completion":119,"start":120,"enrollment":121,"conditions":122,"interventions":124},[59,60],"2028-06-30","2024-12-10",90,[123],"Hypothyroidism",[55,125,126],"Levothyroxine\u002FLiothyronine once daily","Levothyroxine\u002FLiothyronine twice daily",{"trials":128,"activeCount":69},[],{"trials":130,"activeCount":69},[],{"intervention":125,"totalTrials":65,"cells":132},{"EARLY_PHASE1":133,"PHASE1":135,"PHASE2":137,"PHASE3":139,"PHASE4":145,"NA":147},{"trials":134,"activeCount":69},[],{"trials":136,"activeCount":69},[],{"trials":138,"activeCount":69},[],{"trials":140,"activeCount":65,"soonestReadout":54},[141],{"nctId":52,"briefTitle":53,"status":79,"phases":142,"primaryCompletion":54,"completion":119,"start":120,"enrollment":121,"conditions":143,"interventions":144},[59,60],[123],[55,125,126],{"trials":146,"activeCount":69},[],{"trials":148,"activeCount":69},[],{"intervention":126,"totalTrials":65,"cells":150},{"EARLY_PHASE1":151,"PHASE1":153,"PHASE2":155,"PHASE3":157,"PHASE4":163,"NA":165},{"trials":152,"activeCount":69},[],{"trials":154,"activeCount":69},[],{"trials":156,"activeCount":69},[],{"trials":158,"activeCount":65,"soonestReadout":54},[159],{"nctId":52,"briefTitle":53,"status":79,"phases":160,"primaryCompletion":54,"completion":119,"start":120,"enrollment":121,"conditions":161,"interventions":162},[59,60],[123],[55,125,126],{"trials":164,"activeCount":69},[],{"trials":166,"activeCount":69},[],{"intervention":50,"totalTrials":65,"cells":168},{"EARLY_PHASE1":169,"PHASE1":171,"PHASE2":173,"PHASE3":185,"PHASE4":187,"NA":189},{"trials":170,"activeCount":69},[],{"trials":172,"activeCount":69},[],{"trials":174,"activeCount":65,"soonestReadout":49},[175],{"nctId":47,"briefTitle":48,"status":79,"phases":176,"primaryCompletion":49,"completion":177,"start":178,"enrollment":179,"conditions":180,"interventions":184},[59],"2028-02-01","2024-10-07",60,[181,182,183],"Frailty","Mild Cognitive Impairment","Aging",[50],{"trials":186,"activeCount":69},[],{"trials":188,"activeCount":69},[],{"trials":190,"activeCount":69},[],{"intervention":40,"totalTrials":65,"cells":192},{"EARLY_PHASE1":193,"PHASE1":203,"PHASE2":205,"PHASE3":207,"PHASE4":209,"NA":211},{"trials":194,"activeCount":65,"soonestReadout":39},[195],{"nctId":37,"briefTitle":38,"status":196,"phases":197,"primaryCompletion":39,"completion":39,"start":198,"enrollment":199,"conditions":200,"interventions":202},"ACTIVE_NOT_RECRUITING",[57],"2025-05-22",15,[201],"Parkinson Disease, Idiopathic",[40],{"trials":204,"activeCount":69},[],{"trials":206,"activeCount":69},[],{"trials":208,"activeCount":69},[],{"trials":210,"activeCount":69},[],{"trials":212,"activeCount":69},[],{"intervention":214,"totalTrials":215,"cells":216},"naltrexone",3,{"EARLY_PHASE1":217,"PHASE1":219,"PHASE2":221,"PHASE3":223,"PHASE4":225,"NA":256},{"trials":218,"activeCount":69},[],{"trials":220,"activeCount":69},[],{"trials":222,"activeCount":69},[],{"trials":224,"activeCount":69},[],{"trials":226,"activeCount":69},[227,236,244],{"nctId":228,"briefTitle":229,"status":230,"phases":231,"completion":232,"enrollment":233,"conditions":234,"interventions":235},"NCT00000442","Naltrexone for Relapse Prevention","COMPLETED",[61],"2002-12",57,[18],[214],{"nctId":237,"briefTitle":238,"status":230,"phases":239,"completion":240,"enrollment":241,"conditions":242,"interventions":243},"NCT00000455","Naltrexone for Early Problem Drinkers",[61],"2002-09",160,[18],[214],{"nctId":245,"briefTitle":246,"status":230,"phases":247,"primaryCompletion":248,"completion":249,"start":250,"enrollment":251,"conditions":252,"interventions":254},"NCT00369408","Targeted Naltrexone for Problem Drinkers",[61],"2007-08","2008-03","2003-06",163,[18,253,26],"Alcohol Drinking",[255],"Naltrexone",{"trials":257,"activeCount":69},[],{"intervention":259,"totalTrials":260,"cells":261},"Topiramate",2,{"EARLY_PHASE1":262,"PHASE1":264,"PHASE2":266,"PHASE3":268,"PHASE4":281,"NA":293},{"trials":263,"activeCount":69},[],{"trials":265,"activeCount":69},[],{"trials":267,"activeCount":69},[],{"trials":269,"activeCount":69},[270],{"nctId":271,"briefTitle":272,"status":230,"phases":273,"primaryCompletion":274,"completion":275,"start":276,"enrollment":233,"conditions":277,"interventions":279},"NCT00755716","Topiramate Alone and in Combination With the Nicotine Patch for Smoking Cessation: A Pilot Study",[60],"2008-12","2013-08","2006-04",[278],"Tobacco Dependence",[259,280],"Nicotine patch",{"trials":282,"activeCount":69},[283],{"nctId":284,"briefTitle":285,"status":230,"phases":286,"primaryCompletion":287,"completion":287,"start":288,"enrollment":289,"conditions":290,"interventions":291},"NCT00626925","Topiramate Treatment of Problem Drinkers",[61],"2013-11","2008-02",200,[253],[292],"topiramate",{"trials":294,"activeCount":69},[],{"intervention":296,"totalTrials":260,"cells":297},"Dipyridamole",{"EARLY_PHASE1":298,"PHASE1":300,"PHASE2":302,"PHASE3":317,"PHASE4":319,"NA":330},{"trials":299,"activeCount":69},[],{"trials":301,"activeCount":69},[],{"trials":303,"activeCount":69},[304],{"nctId":305,"briefTitle":306,"status":307,"phases":308,"primaryCompletion":309,"completion":310,"start":311,"enrollment":312,"conditions":313,"interventions":316},"NCT04424901","Trial of Open Label Dipyridamole- In Hospitalized Patients With COVID-19","TERMINATED",[59],"2022-03-22","2022-04-24","2020-05-03",41,[314,315],"COVID-19 Pneumonia","Vascular Complications",[296],{"trials":318,"activeCount":69},[],{"trials":320,"activeCount":69},[321],{"nctId":322,"briefTitle":323,"status":307,"phases":324,"primaryCompletion":325,"completion":325,"start":240,"enrollment":24,"conditions":326,"interventions":328},"NCT00763009","Persantine: Variation in Response Trial",[61],"2009-07",[327],"Coronary Artery Disease",[329],"dipyridamole",{"trials":331,"activeCount":69},[],{"intervention":333,"totalTrials":260,"cells":334},"hCG",{"EARLY_PHASE1":335,"PHASE1":337,"PHASE2":339,"PHASE3":341,"PHASE4":343,"NA":366},{"trials":336,"activeCount":69},[],{"trials":338,"activeCount":69},[],{"trials":340,"activeCount":69},[],{"trials":342,"activeCount":69},[],{"trials":344,"activeCount":69},[345,356],{"nctId":346,"briefTitle":347,"status":307,"phases":348,"primaryCompletion":349,"completion":349,"start":350,"enrollment":11,"conditions":351,"interventions":354},"NCT01606709","Gene Expression Profile After Gonadotropin Releasing Hormone (GnRH) Agonist Trigger of Oocyte Maturation",[61],"2014-12","2012-04",[352,353],"Endometrial Receptivity","Ovarian Hyperstimulation Syndrome",[355,333],"GnRH agonist",{"nctId":357,"briefTitle":358,"status":230,"phases":359,"primaryCompletion":360,"completion":361,"start":362,"enrollment":363,"conditions":364,"interventions":365},"NCT01815138","Co-administration of Low Dose hCG at the Time of GnRH Agonist Trigger or 35 Hours Later for the Prevention of OHSS",[61],"2015-12","2016-10","2013-03",89,[353],[333,333],{"trials":367,"activeCount":69},[],{"intervention":369,"totalTrials":65,"cells":370},"Ceftriaxone",{"EARLY_PHASE1":371,"PHASE1":373,"PHASE2":375,"PHASE3":377,"PHASE4":379,"NA":395},{"trials":372,"activeCount":69},[],{"trials":374,"activeCount":69},[],{"trials":376,"activeCount":69},[],{"trials":378,"activeCount":69},[],{"trials":380,"activeCount":69},[381],{"nctId":382,"briefTitle":383,"status":307,"phases":384,"primaryCompletion":385,"completion":385,"start":386,"enrollment":30,"conditions":387,"interventions":390},"NCT05079620","Early Antibiotics After Aspiration in ICU Patients",[61],"2024-04-12","2021-11-30",[388,389],"Aspiration","Aspiration Pneumonia",[369,391,392,393,394],"Amoxicillin clavulanic acid","Cefepime","Vancomycin","Levofloxacin",{"trials":396,"activeCount":69},[],{"intervention":391,"totalTrials":65,"cells":398},{"EARLY_PHASE1":399,"PHASE1":401,"PHASE2":403,"PHASE3":405,"PHASE4":407,"NA":413},{"trials":400,"activeCount":69},[],{"trials":402,"activeCount":69},[],{"trials":404,"activeCount":69},[],{"trials":406,"activeCount":69},[],{"trials":408,"activeCount":69},[409],{"nctId":382,"briefTitle":383,"status":307,"phases":410,"primaryCompletion":385,"completion":385,"start":386,"enrollment":30,"conditions":411,"interventions":412},[61],[388,389],[369,391,392,393,394],{"trials":414,"activeCount":69},[],{"intervention":392,"totalTrials":65,"cells":416},{"EARLY_PHASE1":417,"PHASE1":419,"PHASE2":421,"PHASE3":423,"PHASE4":425,"NA":431},{"trials":418,"activeCount":69},[],{"trials":420,"activeCount":69},[],{"trials":422,"activeCount":69},[],{"trials":424,"activeCount":69},[],{"trials":426,"activeCount":69},[427],{"nctId":382,"briefTitle":383,"status":307,"phases":428,"primaryCompletion":385,"completion":385,"start":386,"enrollment":30,"conditions":429,"interventions":430},[61],[388,389],[369,391,392,393,394],{"trials":432,"activeCount":69},[],{"intervention":393,"totalTrials":65,"cells":434},{"EARLY_PHASE1":435,"PHASE1":437,"PHASE2":439,"PHASE3":441,"PHASE4":443,"NA":449},{"trials":436,"activeCount":69},[],{"trials":438,"activeCount":69},[],{"trials":440,"activeCount":69},[],{"trials":442,"activeCount":69},[],{"trials":444,"activeCount":69},[445],{"nctId":382,"briefTitle":383,"status":307,"phases":446,"primaryCompletion":385,"completion":385,"start":386,"enrollment":30,"conditions":447,"interventions":448},[61],[388,389],[369,391,392,393,394],{"trials":450,"activeCount":69},[],{"intervention":394,"totalTrials":65,"cells":452},{"EARLY_PHASE1":453,"PHASE1":455,"PHASE2":457,"PHASE3":459,"PHASE4":461,"NA":467},{"trials":454,"activeCount":69},[],{"trials":456,"activeCount":69},[],{"trials":458,"activeCount":69},[],{"trials":460,"activeCount":69},[],{"trials":462,"activeCount":69},[463],{"nctId":382,"briefTitle":383,"status":307,"phases":464,"primaryCompletion":385,"completion":385,"start":386,"enrollment":30,"conditions":465,"interventions":466},[61],[388,389],[369,391,392,393,394],{"trials":468,"activeCount":69},[],{"intervention":470,"totalTrials":65,"cells":471},"Guanfacine Extended Release",{"EARLY_PHASE1":472,"PHASE1":474,"PHASE2":476,"PHASE3":478,"PHASE4":480,"NA":492},{"trials":473,"activeCount":69},[],{"trials":475,"activeCount":69},[],{"trials":477,"activeCount":69},[],{"trials":479,"activeCount":69},[],{"trials":481,"activeCount":69},[482],{"nctId":483,"briefTitle":484,"status":485,"phases":486,"primaryCompletion":487,"completion":487,"start":488,"enrollment":69,"conditions":489,"interventions":491},"NCT03258476","Guanfacine Extended Release and Mindfulness Skills Therapy","WITHDRAWN",[61],"2019-12-03","2019-03-01",[490],"Stress Disorder",[470],{"trials":493,"activeCount":69},[],{"intervention":495,"totalTrials":65,"cells":496},"zonisamide",{"EARLY_PHASE1":497,"PHASE1":499,"PHASE2":501,"PHASE3":503,"PHASE4":505,"NA":516},{"trials":498,"activeCount":69},[],{"trials":500,"activeCount":69},[],{"trials":502,"activeCount":69},[],{"trials":504,"activeCount":69},[],{"trials":506,"activeCount":69},[507],{"nctId":508,"briefTitle":509,"status":230,"phases":510,"primaryCompletion":511,"completion":511,"start":512,"enrollment":513,"conditions":514,"interventions":515},"NCT00595556","Zonisamide vs. Placebo in the Treatment of Alcohol Dependence",[61],"2009-05","2006-07",40,[18,21,26],[495],{"trials":517,"activeCount":69},[],{"intervention":355,"totalTrials":65,"cells":519},{"EARLY_PHASE1":520,"PHASE1":522,"PHASE2":524,"PHASE3":526,"PHASE4":528,"NA":534},{"trials":521,"activeCount":69},[],{"trials":523,"activeCount":69},[],{"trials":525,"activeCount":69},[],{"trials":527,"activeCount":69},[],{"trials":529,"activeCount":69},[530],{"nctId":346,"briefTitle":347,"status":307,"phases":531,"primaryCompletion":349,"completion":349,"start":350,"enrollment":11,"conditions":532,"interventions":533},[61],[352,353],[355,333],{"trials":535,"activeCount":69},[],{"intervention":537,"totalTrials":65,"cells":538},"Tranexamic Acid",{"EARLY_PHASE1":539,"PHASE1":541,"PHASE2":543,"PHASE3":545,"PHASE4":547,"NA":559},{"trials":540,"activeCount":69},[],{"trials":542,"activeCount":69},[],{"trials":544,"activeCount":69},[],{"trials":546,"activeCount":69},[],{"trials":548,"activeCount":69},[549],{"nctId":550,"briefTitle":551,"status":230,"phases":552,"primaryCompletion":553,"completion":553,"start":554,"enrollment":555,"conditions":556,"interventions":558},"NCT02664909","Topical (Intra-Articular) Tranexamic Acid and Transfusion Rates Following Hip Hemiarthroplasty",[61],"2019-06-30","2016-01-01",36,[557],"Femoral Neck Fractures",[537],{"trials":560,"activeCount":69},[],{"intervention":562,"totalTrials":65,"cells":563},"Sertraline",{"EARLY_PHASE1":564,"PHASE1":566,"PHASE2":568,"PHASE3":570,"PHASE4":572,"NA":584},{"trials":565,"activeCount":69},[],{"trials":567,"activeCount":69},[],{"trials":569,"activeCount":69},[],{"trials":571,"activeCount":69},[],{"trials":573,"activeCount":69},[574],{"nctId":575,"briefTitle":576,"status":230,"phases":577,"primaryCompletion":578,"completion":579,"start":580,"enrollment":581,"conditions":582,"interventions":583},"NCT00368550","Sertraline Pharmacotherapy for Alcoholism Subtypes",[61],"2009-06","2009-12","2004-02",134,[18],[562],{"trials":585,"activeCount":69},[],{"intervention":587,"totalTrials":65,"cells":588},"Aliskiren",{"EARLY_PHASE1":589,"PHASE1":591,"PHASE2":593,"PHASE3":595,"PHASE4":597,"NA":609},{"trials":590,"activeCount":69},[],{"trials":592,"activeCount":69},[],{"trials":594,"activeCount":69},[],{"trials":596,"activeCount":69},[],{"trials":598,"activeCount":69},[599],{"nctId":600,"briefTitle":601,"status":307,"phases":602,"primaryCompletion":603,"completion":603,"start":604,"enrollment":513,"conditions":605,"interventions":608},"NCT00974922","Vitamin D Deficiency in Patients With Hypertension",[61],"2011-12","2009-08",[606,607],"Vitamin D Deficiency","Hypertension",[587],{"trials":610,"activeCount":69},[],{"intervention":612,"totalTrials":65,"cells":613},"Varenicline",{"EARLY_PHASE1":614,"PHASE1":616,"PHASE2":618,"PHASE3":620,"PHASE4":622,"NA":634},{"trials":615,"activeCount":69},[],{"trials":617,"activeCount":69},[],{"trials":619,"activeCount":69},[],{"trials":621,"activeCount":69},[],{"trials":623,"activeCount":69},[624],{"nctId":625,"briefTitle":626,"status":230,"phases":627,"primaryCompletion":628,"completion":629,"start":630,"enrollment":631,"conditions":632,"interventions":633},"NCT00879177","Smoking Study With Behavioral Therapy for Hypertensive Patients",[61],"2014-08","2014-11","2009-04",203,[34,607],[612],{"trials":635,"activeCount":69},[],{"intervention":637,"totalTrials":65,"cells":638},"Ketorolac Tromethamine",{"EARLY_PHASE1":639,"PHASE1":641,"PHASE2":643,"PHASE3":645,"PHASE4":647,"NA":661},{"trials":640,"activeCount":69},[],{"trials":642,"activeCount":69},[],{"trials":644,"activeCount":69},[],{"trials":646,"activeCount":69},[],{"trials":648,"activeCount":69},[649],{"nctId":650,"briefTitle":651,"status":307,"phases":652,"primaryCompletion":653,"completion":653,"start":654,"enrollment":655,"conditions":656,"interventions":658},"NCT03694821","Knee Injection RCT",[61],"2019-07-16","2018-07-05",18,[657],"Osteoarthritis",[637,659,660],"Methylprednisolone Acetate","Hylan G-F 20",{"trials":662,"activeCount":69},[],{"intervention":659,"totalTrials":65,"cells":664},{"EARLY_PHASE1":665,"PHASE1":667,"PHASE2":669,"PHASE3":671,"PHASE4":673,"NA":679},{"trials":666,"activeCount":69},[],{"trials":668,"activeCount":69},[],{"trials":670,"activeCount":69},[],{"trials":672,"activeCount":69},[],{"trials":674,"activeCount":69},[675],{"nctId":650,"briefTitle":651,"status":307,"phases":676,"primaryCompletion":653,"completion":653,"start":654,"enrollment":655,"conditions":677,"interventions":678},[61],[657],[637,659,660],{"trials":680,"activeCount":69},[],{"intervention":660,"totalTrials":65,"cells":682},{"EARLY_PHASE1":683,"PHASE1":685,"PHASE2":687,"PHASE3":689,"PHASE4":691,"NA":697},{"trials":684,"activeCount":69},[],{"trials":686,"activeCount":69},[],{"trials":688,"activeCount":69},[],{"trials":690,"activeCount":69},[],{"trials":692,"activeCount":69},[693],{"nctId":650,"briefTitle":651,"status":307,"phases":694,"primaryCompletion":653,"completion":653,"start":654,"enrollment":655,"conditions":695,"interventions":696},[61],[657],[637,659,660],{"trials":698,"activeCount":69},[],{"intervention":700,"totalTrials":65,"cells":701},"risedronate",{"EARLY_PHASE1":702,"PHASE1":704,"PHASE2":706,"PHASE3":708,"PHASE4":710,"NA":722},{"trials":703,"activeCount":69},[],{"trials":705,"activeCount":69},[],{"trials":707,"activeCount":69},[],{"trials":709,"activeCount":69},[],{"trials":711,"activeCount":69},[712],{"nctId":713,"briefTitle":714,"status":230,"phases":715,"primaryCompletion":249,"completion":716,"start":717,"enrollment":718,"conditions":719,"interventions":721},"NCT00859027","Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer",[61],"2009-02","2003-01",50,[720],"Prostate Cancer",[700],{"trials":723,"activeCount":69},[],{"intervention":725,"totalTrials":65,"cells":726},"Nicotrol Inhaler",{"EARLY_PHASE1":727,"PHASE1":729,"PHASE2":731,"PHASE3":733,"PHASE4":735,"NA":749},{"trials":728,"activeCount":69},[],{"trials":730,"activeCount":69},[],{"trials":732,"activeCount":69},[],{"trials":734,"activeCount":69},[],{"trials":736,"activeCount":69},[737],{"nctId":738,"briefTitle":739,"status":230,"phases":740,"primaryCompletion":741,"completion":742,"start":743,"enrollment":744,"conditions":745,"interventions":748},"NCT01656733","Nicotine Replacement for Smoking Cessation During Pregnancy",[61],"2017-09-30","2017-10-25","2012-08",154,[746,747],"Nicotine Dependence","Smoking Cessation",[725],{"trials":750,"activeCount":69},[],{"intervention":752,"totalTrials":65,"cells":753},"sugar pill",{"EARLY_PHASE1":754,"PHASE1":756,"PHASE2":758,"PHASE3":760,"PHASE4":762,"NA":774},{"trials":755,"activeCount":69},[],{"trials":757,"activeCount":69},[],{"trials":759,"activeCount":69},[],{"trials":761,"activeCount":69},[],{"trials":763,"activeCount":69},[764],{"nctId":765,"briefTitle":766,"status":230,"phases":767,"primaryCompletion":768,"completion":768,"start":769,"enrollment":770,"conditions":771,"interventions":772},"NCT01758523","Dutasteride Treatment for the Reduction of Heavy Drinking in Men",[61],"2018-02-28","2013-01",189,[18,21,26],[773,752],"Dutasteride",{"trials":775,"activeCount":69},[],{"intervention":280,"totalTrials":65,"cells":777},{"EARLY_PHASE1":778,"PHASE1":780,"PHASE2":782,"PHASE3":784,"PHASE4":790,"NA":792},{"trials":779,"activeCount":69},[],{"trials":781,"activeCount":69},[],{"trials":783,"activeCount":69},[],{"trials":785,"activeCount":69},[786],{"nctId":271,"briefTitle":272,"status":230,"phases":787,"primaryCompletion":274,"completion":275,"start":276,"enrollment":233,"conditions":788,"interventions":789},[60],[278],[259,280],{"trials":791,"activeCount":69},[],{"trials":793,"activeCount":69},[],{"intervention":795,"totalTrials":65,"cells":796},"Theophylline",{"EARLY_PHASE1":797,"PHASE1":799,"PHASE2":801,"PHASE3":803,"PHASE4":815,"NA":817},{"trials":798,"activeCount":69},[],{"trials":800,"activeCount":69},[],{"trials":802,"activeCount":69},[],{"trials":804,"activeCount":69},[805],{"nctId":806,"briefTitle":807,"status":230,"phases":808,"primaryCompletion":809,"completion":809,"start":349,"enrollment":810,"conditions":811,"interventions":813},"NCT02340520","Enhancement of Corticosteroid Efficacy in COPD",[60],"2016-08",13,[812],"COPD",[795,814],"Roflumilast",{"trials":816,"activeCount":69},[],{"trials":818,"activeCount":69},[],{"intervention":814,"totalTrials":65,"cells":820},{"EARLY_PHASE1":821,"PHASE1":823,"PHASE2":825,"PHASE3":827,"PHASE4":833,"NA":835},{"trials":822,"activeCount":69},[],{"trials":824,"activeCount":69},[],{"trials":826,"activeCount":69},[],{"trials":828,"activeCount":69},[829],{"nctId":806,"briefTitle":807,"status":230,"phases":830,"primaryCompletion":809,"completion":809,"start":349,"enrollment":810,"conditions":831,"interventions":832},[60],[812],[795,814],{"trials":834,"activeCount":69},[],{"trials":836,"activeCount":69},[],{"intervention":838,"totalTrials":65,"cells":839},"Desvenlafaxine",{"EARLY_PHASE1":840,"PHASE1":842,"PHASE2":844,"PHASE3":846,"PHASE4":860,"NA":862},{"trials":841,"activeCount":69},[],{"trials":843,"activeCount":69},[],{"trials":845,"activeCount":69},[],{"trials":847,"activeCount":69},[848],{"nctId":849,"briefTitle":850,"status":307,"phases":851,"primaryCompletion":852,"completion":852,"start":853,"enrollment":27,"conditions":854,"interventions":859},"NCT01803711","Omega 3 FA Supplements as Augmentation in the Treatment of Depression",[59,60],"2016-06","2013-02",[855,856,857,858],"Major Depression","Cancer","Diabetes","Cardiovascular Diseases",[838],{"trials":861,"activeCount":69},[],{"trials":863,"activeCount":69},[],{"intervention":865,"totalTrials":65,"cells":866},"Thyrotropin releasing hormone",{"EARLY_PHASE1":867,"PHASE1":869,"PHASE2":871,"PHASE3":883,"PHASE4":885,"NA":887},{"trials":868,"activeCount":69},[],{"trials":870,"activeCount":69},[],{"trials":872,"activeCount":69},[873],{"nctId":874,"briefTitle":875,"status":307,"phases":876,"primaryCompletion":877,"completion":878,"start":879,"enrollment":16,"conditions":880,"interventions":882},"NCT00790296","Evaluation of Synthetic Thyrotropin Releasing Hormone (TRH) as a Treatment for Cancer-related Fatigue",[59],"2010-02","2010-03","2006-12",[881],"Cancer-related Fatigue",[865],{"trials":884,"activeCount":69},[],{"trials":886,"activeCount":69},[],{"trials":888,"activeCount":69},[],{"intervention":890,"totalTrials":65,"cells":891},"transdermal nicotine",{"EARLY_PHASE1":892,"PHASE1":894,"PHASE2":896,"PHASE3":905,"PHASE4":907,"NA":909},{"trials":893,"activeCount":69},[],{"trials":895,"activeCount":69},[],{"trials":897,"activeCount":69},[898],{"nctId":899,"briefTitle":900,"status":230,"phases":901,"primaryCompletion":349,"completion":349,"start":902,"enrollment":121,"conditions":903,"interventions":904},"NCT01484717","Interactive Voice Response Technology to Mobilize Contingency Management for Smoking Cessation",[59],"2012-01",[34],[890],{"trials":906,"activeCount":69},[],{"trials":908,"activeCount":69},[],{"trials":910,"activeCount":69},[],{"intervention":912,"totalTrials":65,"cells":913},"Heat Shock Protein 70-peptide complexes",{"EARLY_PHASE1":914,"PHASE1":916,"PHASE2":918,"PHASE3":929,"PHASE4":931,"NA":933},{"trials":915,"activeCount":69},[],{"trials":917,"activeCount":69},[],{"trials":919,"activeCount":69},[920],{"nctId":921,"briefTitle":922,"status":307,"phases":923,"completion":924,"start":925,"enrollment":199,"conditions":926,"interventions":928},"NCT00027131","Vaccination Against High Risk Breast Cancer Using Tumor Derived Heat Shock Protein 70",[58,59],"2002-10","2000-12",[927],"Breast Neoplasms",[912],{"trials":930,"activeCount":69},[],{"trials":932,"activeCount":69},[],{"trials":934,"activeCount":69},[],{"intervention":936,"totalTrials":65,"cells":937},"bosentan",{"EARLY_PHASE1":938,"PHASE1":940,"PHASE2":942,"PHASE3":952,"PHASE4":954,"NA":956},{"trials":939,"activeCount":69},[],{"trials":941,"activeCount":69},[],{"trials":943,"activeCount":69},[944],{"nctId":945,"briefTitle":946,"status":307,"phases":947,"primaryCompletion":948,"completion":948,"start":274,"enrollment":16,"conditions":949,"interventions":951},"NCT00815347","Bosentan for Poorly Controlled Asthma",[59],"2010-09",[950],"Asthma",[936],{"trials":953,"activeCount":69},[],{"trials":955,"activeCount":69},[],{"trials":957,"activeCount":69},[],{"intervention":959,"totalTrials":65,"cells":960},"Bevacizumab",{"EARLY_PHASE1":961,"PHASE1":963,"PHASE2":965,"PHASE3":982,"PHASE4":984,"NA":986},{"trials":962,"activeCount":69},[],{"trials":964,"activeCount":69},[],{"trials":966,"activeCount":69},[967],{"nctId":968,"briefTitle":969,"status":307,"phases":970,"primaryCompletion":604,"completion":971,"start":972,"enrollment":30,"conditions":973,"interventions":979},"NCT00408070","Bevacizumab Study With Carboplatin & Paclitaxel in Ovarian, Fallopian Tube or Primary Peritoneal Cancer",[59],"2009-10","2006-10",[974,975,976,977,978],"Ovarian Cancer","Peritoneal Cancer","Fallopian Tube Cancer","Stage 3 Cancer","Stage 4 Cancer",[959,980,981],"Carboplatin","Paclitaxel",{"trials":983,"activeCount":69},[],{"trials":985,"activeCount":69},[],{"trials":987,"activeCount":69},[],{"intervention":980,"totalTrials":65,"cells":989},{"EARLY_PHASE1":990,"PHASE1":992,"PHASE2":994,"PHASE3":1000,"PHASE4":1002,"NA":1004},{"trials":991,"activeCount":69},[],{"trials":993,"activeCount":69},[],{"trials":995,"activeCount":69},[996],{"nctId":968,"briefTitle":969,"status":307,"phases":997,"primaryCompletion":604,"completion":971,"start":972,"enrollment":30,"conditions":998,"interventions":999},[59],[974,975,976,977,978],[959,980,981],{"trials":1001,"activeCount":69},[],{"trials":1003,"activeCount":69},[],{"trials":1005,"activeCount":69},[],{"intervention":981,"totalTrials":65,"cells":1007},{"EARLY_PHASE1":1008,"PHASE1":1010,"PHASE2":1012,"PHASE3":1018,"PHASE4":1020,"NA":1022},{"trials":1009,"activeCount":69},[],{"trials":1011,"activeCount":69},[],{"trials":1013,"activeCount":69},[1014],{"nctId":968,"briefTitle":969,"status":307,"phases":1015,"primaryCompletion":604,"completion":971,"start":972,"enrollment":30,"conditions":1016,"interventions":1017},[59],[974,975,976,977,978],[959,980,981],{"trials":1019,"activeCount":69},[],{"trials":1021,"activeCount":69},[],{"trials":1023,"activeCount":69},[],{"intervention":1025,"totalTrials":65,"cells":1026},"celecoxib",{"EARLY_PHASE1":1027,"PHASE1":1029,"PHASE2":1031,"PHASE3":1044,"PHASE4":1046,"NA":1048},{"trials":1028,"activeCount":69},[],{"trials":1030,"activeCount":69},[],{"trials":1032,"activeCount":69},[1033],{"nctId":1034,"briefTitle":1035,"status":230,"phases":1036,"primaryCompletion":1037,"completion":1038,"start":1039,"enrollment":1040,"conditions":1041,"interventions":1043},"NCT00698204","Cox-2 Inhibition in Radiation-induced Oral Mucositis",[59],"2012-09","2013-12","2003-07",43,[1042],"Oral Mucositis",[1025],{"trials":1045,"activeCount":69},[],{"trials":1047,"activeCount":69},[],{"trials":1049,"activeCount":69},[],{"intervention":1051,"totalTrials":65,"cells":1052},"Metformin Hydrochloride Extended-Release",{"EARLY_PHASE1":1053,"PHASE1":1055,"PHASE2":1069,"PHASE3":1071,"PHASE4":1073,"NA":1075},{"trials":1054,"activeCount":69},[],{"trials":1056,"activeCount":69},[1057],{"nctId":1058,"briefTitle":1059,"status":230,"phases":1060,"primaryCompletion":1061,"completion":1061,"start":1062,"enrollment":1063,"conditions":1064,"interventions":1067},"NCT03996538","Vaccination Efficacy With Metformin in Older Adults",[58],"2020-02-04","2019-06-05",26,[183,1065,1066],"Age-Related Immunodeficiency","Vaccine Response Impaired",[1051,1068],"Influenza Vaccine",{"trials":1070,"activeCount":69},[],{"trials":1072,"activeCount":69},[],{"trials":1074,"activeCount":69},[],{"trials":1076,"activeCount":69},[],{"intervention":1068,"totalTrials":65,"cells":1078},{"EARLY_PHASE1":1079,"PHASE1":1081,"PHASE2":1087,"PHASE3":1089,"PHASE4":1091,"NA":1093},{"trials":1080,"activeCount":69},[],{"trials":1082,"activeCount":69},[1083],{"nctId":1058,"briefTitle":1059,"status":230,"phases":1084,"primaryCompletion":1061,"completion":1061,"start":1062,"enrollment":1063,"conditions":1085,"interventions":1086},[58],[183,1065,1066],[1051,1068],{"trials":1088,"activeCount":69},[],{"trials":1090,"activeCount":69},[],{"trials":1092,"activeCount":69},[],{"trials":1094,"activeCount":69},[],{"intervention":1096,"totalTrials":65,"cells":1097},"OncoImmunome",{"EARLY_PHASE1":1098,"PHASE1":1100,"PHASE2":1110,"PHASE3":1112,"PHASE4":1114,"NA":1116},{"trials":1099,"activeCount":69},[],{"trials":1101,"activeCount":69},[1102],{"nctId":1103,"briefTitle":1104,"status":307,"phases":1105,"primaryCompletion":1106,"completion":1106,"start":1107,"enrollment":24,"conditions":1108,"interventions":1109},"NCT02933073","Study of Oncoimmunome for the Treatment of Stage III\u002FIV Ovarian Carcinoma",[58],"2022-08","2016-11",[974],[1096],{"trials":1111,"activeCount":69},[],{"trials":1113,"activeCount":69},[],{"trials":1115,"activeCount":69},[],{"trials":1117,"activeCount":69},[],{"intervention":1119,"totalTrials":65,"cells":1120},"recombinant 70-kD heat-shock protein",{"EARLY_PHASE1":1121,"PHASE1":1123,"PHASE2":1135,"PHASE3":1137,"PHASE4":1139,"NA":1141},{"trials":1122,"activeCount":69},[],{"trials":1124,"activeCount":69},[1125],{"nctId":1126,"briefTitle":1127,"status":230,"phases":1128,"primaryCompletion":1129,"completion":1129,"start":1130,"enrollment":1131,"conditions":1132,"interventions":1134},"NCT00030303","Vaccine Therapy in Treating Patients With Chronic Myelogenous Leukemia",[58],"2004-01","2001-01",20,[1133],"Leukemia",[1119],{"trials":1136,"activeCount":69},[],{"trials":1138,"activeCount":69},[],{"trials":1140,"activeCount":69},[],{"trials":1142,"activeCount":69},[],{"intervention":1144,"totalTrials":65,"cells":1145},"Freeze-dried black raspberry powder",{"EARLY_PHASE1":1146,"PHASE1":1148,"PHASE2":1159,"PHASE3":1161,"PHASE4":1163,"NA":1165},{"trials":1147,"activeCount":69},[],{"trials":1149,"activeCount":69},[1150],{"nctId":1151,"briefTitle":1152,"status":230,"phases":1153,"primaryCompletion":1154,"completion":1155,"start":275,"enrollment":11,"conditions":1156,"interventions":1158},"NCT02267694","Study of Freeze-dried Black Raspberry in Maintenance of Ulcerative Colitis",[58],"2015-10-05","2015-11-13",[1157],"Ulcerative Colitis",[1144],{"trials":1160,"activeCount":69},[],{"trials":1162,"activeCount":69},[],{"trials":1164,"activeCount":69},[],{"trials":1166,"activeCount":69},[],{"intervention":1168,"totalTrials":65,"cells":1169},"Dornase alfa",{"EARLY_PHASE1":1170,"PHASE1":1172,"PHASE2":1185,"PHASE3":1187,"PHASE4":1189,"NA":1191},{"trials":1171,"activeCount":69},[],{"trials":1173,"activeCount":69},[1174],{"nctId":1175,"briefTitle":1176,"status":485,"phases":1177,"primaryCompletion":1178,"completion":1178,"start":1179,"enrollment":69,"conditions":1180,"interventions":1183},"NCT01357447","Pulmozyme for Sjogren's Associated Cough",[58],"2012-03","2011-05",[1181,1182],"Sjogren's Syndrome","Cough",[1168,1184],"Saline",{"trials":1186,"activeCount":69},[],{"trials":1188,"activeCount":69},[],{"trials":1190,"activeCount":69},[],{"trials":1192,"activeCount":69},[],{"intervention":1184,"totalTrials":65,"cells":1194},{"EARLY_PHASE1":1195,"PHASE1":1197,"PHASE2":1203,"PHASE3":1205,"PHASE4":1207,"NA":1209},{"trials":1196,"activeCount":69},[],{"trials":1198,"activeCount":69},[1199],{"nctId":1175,"briefTitle":1176,"status":485,"phases":1200,"primaryCompletion":1178,"completion":1178,"start":1179,"enrollment":69,"conditions":1201,"interventions":1202},[58],[1181,1182],[1168,1184],{"trials":1204,"activeCount":69},[],{"trials":1206,"activeCount":69},[],{"trials":1208,"activeCount":69},[],{"trials":1210,"activeCount":69},[],{"intervention":773,"totalTrials":1212,"cells":1213},4,{"EARLY_PHASE1":1214,"PHASE1":1216,"PHASE2":1218,"PHASE3":1220,"PHASE4":1232,"NA":1247},{"trials":1215,"activeCount":69},[],{"trials":1217,"activeCount":69},[],{"trials":1219,"activeCount":69},[],{"trials":1221,"activeCount":69},[1222],{"nctId":1223,"briefTitle":1224,"status":230,"phases":1225,"primaryCompletion":1226,"completion":1226,"start":1227,"enrollment":1228,"conditions":1229,"interventions":1231},"NCT04098302","Dutasteride Treatment for Reducing Heavy Drinking in AUD: Predictors of Efficacy",[59,60],"2024-06-28","2019-10-15",180,[1230],"Alcohol Use Disorder",[773],{"trials":1233,"activeCount":69},[1234,1243],{"nctId":1235,"briefTitle":1236,"status":230,"phases":1237,"primaryCompletion":1238,"completion":1238,"start":1239,"enrollment":1240,"conditions":1241,"interventions":1242},"NCT01262287","Dutasteride for the Reduction of Alcohol Use in Male Drinkers",[61],"2012-12","2011-01",47,[18,21,26],[773],{"nctId":765,"briefTitle":766,"status":230,"phases":1244,"primaryCompletion":768,"completion":768,"start":769,"enrollment":770,"conditions":1245,"interventions":1246},[61],[18,21,26],[773,752],{"trials":1248,"activeCount":69},[1249],{"nctId":1250,"briefTitle":1251,"status":230,"phases":1252,"primaryCompletion":1253,"completion":1253,"start":276,"enrollment":513,"conditions":1254,"interventions":1256},"NCT00802321","Pharmacokinetic Study of Single Dose Dutasteride in Healthy Subjects",[62],"2006-11",[1255,18,21],"Alcohol Related Disorders",[773],{"intervention":1258,"totalTrials":65,"cells":1259},"Nicotine with Tobacco Flavor and Tobacco & Menthol Flavor",{"EARLY_PHASE1":1260,"PHASE1":1262,"PHASE2":1264,"PHASE3":1266,"PHASE4":1268,"NA":1270},{"trials":1261,"activeCount":69},[],{"trials":1263,"activeCount":69},[],{"trials":1265,"activeCount":69},[],{"trials":1267,"activeCount":69},[],{"trials":1269,"activeCount":69},[],{"trials":1271,"activeCount":69},[1272],{"nctId":1273,"briefTitle":1274,"status":230,"phases":1275,"primaryCompletion":1276,"completion":1276,"start":1277,"enrollment":8,"conditions":1278,"interventions":1280},"NCT01775787","Effects of Electronic Cigarettes on Nicotine Concentrations",[62],"2015-06","2012-10",[1279],"Health Behavior",[1258],{"intervention":1282,"totalTrials":65,"cells":1283},"dutasteride + ethanol",{"EARLY_PHASE1":1284,"PHASE1":1286,"PHASE2":1288,"PHASE3":1290,"PHASE4":1292,"NA":1294},{"trials":1285,"activeCount":69},[],{"trials":1287,"activeCount":69},[],{"trials":1289,"activeCount":69},[],{"trials":1291,"activeCount":69},[],{"trials":1293,"activeCount":69},[],{"trials":1295,"activeCount":69},[1296],{"nctId":1297,"briefTitle":1298,"status":230,"phases":1299,"primaryCompletion":1300,"completion":1301,"start":1302,"enrollment":1303,"conditions":1304,"interventions":1305},"NCT00734656","Pharmacogenetics of Alcohol: Treatment Implications",[62],"2010-10","2011-07","2007-03",94,[1255,18,21],[1282,1306],"dutasteride + placebo alcohol",{"intervention":1306,"totalTrials":65,"cells":1308},{"EARLY_PHASE1":1309,"PHASE1":1311,"PHASE2":1313,"PHASE3":1315,"PHASE4":1317,"NA":1319},{"trials":1310,"activeCount":69},[],{"trials":1312,"activeCount":69},[],{"trials":1314,"activeCount":69},[],{"trials":1316,"activeCount":69},[],{"trials":1318,"activeCount":69},[],{"trials":1320,"activeCount":69},[1321],{"nctId":1297,"briefTitle":1298,"status":230,"phases":1322,"primaryCompletion":1300,"completion":1301,"start":1302,"enrollment":1303,"conditions":1323,"interventions":1324},[62],[1255,18,21],[1282,1306]]